Immunotherapy uses the patient’s own immune system and, in addition to the aforementioned monoclonal antibodies in the treatment of HER2-positive cancer, has found its application to an even wider extent in the case of TNBC therapy, because here it has the potential to significantly affect the quality of life of patients by reducing the share of classic chemotherapy [77]. The gene discussed is ERBB2; the disease is cancer.